Why CytoSorbents Has The BIO CEO Investor Community Buzzing

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

Hosting the BIO Buzz Center during the 2018 BIO CEO & Investor Conference in New York City on behalf of Life Science Leader magazine provided me the unique opportunity to conduct video interviews with a number of top industry executives. One of the people I spoke with was Philip Chan, M.D., Ph.D., president, CEO of CytoSorbents. The New Jersey-based pharma  specializes in blood purification technology to control deadly inflammation in critically ill and cardiac surgery patients. The company’s lead product, CytoSorb, is a plug-and-play cartridge filled with advanced, biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Approved in the EU, CytoSorb has distribution in 44 countries around the world and is in the process of seeking FDA approval in the U.S. Prior to Dr. Chan joining CytoSorbents, he led healthcare and life science investments as a partner for the $80 million NJTC Venture Fund, where he was responsible for numerous investments in therapeutics, medical devices, and diagnostics. Below is my short BIO Buzz Center video interview with him.